Used in targeted drug delivery systems, particularly in liver-specific therapies. Its primary application lies in enabling selective uptake of therapeutic agents by hepatocytes through the asialoglycoprotein receptor (ASGPR) pathway. This makes it valuable in the development of siRNA, antisense oligonucleotides, and other nucleic acid-based treatments for liver diseases such as hepatitis, metabolic disorders, and certain cancers. The L96 linker component enhances stability and bioavailability, allowing for improved pharmacokinetics and reduced off-target effects. Commonly employed in conjugate designs to enhance cellular internalization and endosomal escape, contributing to higher potency of the associated drug payload.